Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insiders Are Dumping Flextronics International. Should You Be Scared?

On an up day for stock markets generally, shares of contract electronics manufacturer Flextronics International (NASDAQ:FLEX) stood pat Wednesday, opening the day at $11.31 a share — and closing the day there as well.

Helping to keep a lid on the stock price, one imagines, is the uninspiring insider trading activity that Flextronics reported last month. This activity ended with Wednesday’s filing of a Form 4 detailing CEO Michael McNamara’s sale of 91,324 shares for more than $1 million in proceeds, but it didn’t begin there.

In fact, according to filings with the SEC, insiders at Flextronics have been cashing out in droves — 42 insider sales transactions recorded over the past three months, versus just 18 buys, and with a net of 3.9 million more shares sold than bought by company insiders.

What does it mean to you?
That probably sounds worrisome to some investors. And in fact, it probably would be worrisome — if the other numbers we see at Flextronics weren’t so very, very attractive.

According to Yahoo! Finance data, Flextronics sells for a market cap of $6.4 billion today, but earned more than $600 million in profits over the past 12 months. As a result, the company’s price-to-earnings ratio is a very modest 11.1. In light of analyst estimates that Flextronics will grow those earnings at 14% annually over the next five years, that doesn’t seem expensive at all.

Granted, there are some risks to the company — revenues down 11.5% last quarter, and a sizeable debt load ($700 million more debt than cash on the balance sheet) to name two. Free cash flow at the firm  ($447 million) lags reported net income by a wide margin as well. But even so, the worst I can say about the stock right now is that if the growth rate is accurate, the firm’s enterprise value-to-free cash flow ratio looks a little bit high at 16.4.

Long story short, this stock looks to be anywhere from significantly undervalued in the best case, to just slightly overvalued in the worst.


This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it “transformative”… But you’ll probably just call it “how I made my millions.” Don’t be too late to the party — click here for one stock to own when the Web goes dark.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!